Document is current
Any future updates will be listed below
-
Authors
Ratheesh, Aswin https://orcid.org/0000-0002-8029-9422
Hammond, Dylan https://orcid.org/0000-0002-3310-9200
Gao, Caroline https://orcid.org/0000-0002-0987-2759
Marwaha, Steven
Thompson, Andrew
Hartmann, Jessica
Davey, Christopher https://orcid.org/0000-0003-1431-3852
Zammit, Stanley
Berk, Michael
McGorry, Patrick
Nelson, Barnaby
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council
RCUK | Medical Research Council
Wellcome Trust
Society for Mental Health Research, Australia
University of Bristol
- License Information
-
More Information
Article History
Received: 30 August 2022
Revised: 24 February 2023
Accepted: 10 March 2023
First Online: 29 March 2023
Competing interests
: PM has received past unrestricted grant funding from Janssen-Cilag, Astra Zeneca, Eli Lilly, Novartis, and Pfizer, and honoraria for consultancy and teaching from Janssen-Cilag, Eli Lilly, Pfizer, Astra Zeneca, Roche, Bristol-Meyers Squibb, and Lundbeck. He has received grant funding from the Colonial Foundation, the National Health and Medical Research Council of Australia, NARSAD, the Stanley Foundation, NIH, Wellcome Trust, and the Australian and Victorian governments. MB has received grants, speaker or consultancy fees from RANZCP, Abbott India, ASCP, Headspace, Sandoz, Milken Institute, Aust Psychosis, Lundbeck, Controversias Barcelona, Servier, Medisquire, HealthEd, ANZJP, EPA, Janssen, Medplan, Wellcome Trust, MRFF, Victorian Medical Research Acceleration Fund, Centre for Research Excellence CRE, Victorian Government Department of Jobs, Precincts and Regions- Victorian COVID-19 Research Fund. AR, SM, AT, CD, DH, CG, JH, BN, SZ have no conflicts to declare.
